amifostine anhydrous has been researched along with losartan potassium in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (13.33) | 18.2507 |
| 2000's | 13 (86.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Armenaki, A; Frangiadaki, C; Georgoulias, V; Giatromanolaki, A; Helidonis, E; Koukourakis, MI; Koumandakis, E; Kranidis, A; Stefanaki, I | 1 |
| Ciolli, S; Fabbri, A; Grossi, A; Leoni, F; Longo, G; Nozzoli, C; Pagliai, G; Rossi Ferrini, P; Santini, V | 1 |
| Crawford, J; Foote, M; Morstyn, G | 1 |
| Dispenzieria, A; Elliott, MA; Hanson, CA; Hook, CC; Letendre, L; Schroeder, G; Steensma, DP; Tefferi, A | 1 |
| Bourantas, KL; Christou, L; Kapsali, HD; Panteli, K; Tsiara, SN | 1 |
| Eibl, M; Jaeger, G; Linkesch, W; Neumeister, P; Sormann, S; Zinke, W | 1 |
| Balestri, F; Fabbri, A; Falcone, A; Grossi, A; Musto, P; Sanpaolo, G; Santini, V | 1 |
| Chrissafidou, A; Malek, M; Musch, E | 1 |
| Cetin, E; Müftüoğlu, S; Orhan, B; Sarer, B; Yalcin, S; Yildirim, BA; Zeybek, D | 1 |
| Bartelt, S; Henke, M; Momm, F; Weissenberger, C | 1 |
| Fan, H; Lu, XC; Yang, Y; Yao, SQ; Zhu, HL; Zhuang, XM | 1 |
| Erman, M; Kilickap, S; Temucin, CM; Yalcin, S | 1 |
| Cai, LL; Fan, H; Li, SX; Lu, XC; Ma, J; Yang, QM; Yang, Y; Yao, SQ; Zhu, HL; Zhuang, XM | 1 |
| Cho, KH; Han, HS; Han, JY; Kim, HT; Kim, HY; Lee, DH; Lee, JS; Pyo, HR; Yu, SY | 1 |
| Fan, H; Guo, B; Li, SX; Lu, XC; Zhai, B; Zhu, HL | 1 |
1 review(s) available for amifostine anhydrous and losartan potassium
| Article | Year |
|---|---|
Hematopoietic growth factors in cancer chemotherapy.
Topics: Amifostine; Animals; Erythropoietin; Granulocyte Colony-Stimulating Factor; Granulocyte-Macrophage Colony-Stimulating Factor; Hematopoietic Cell Growth Factors; Humans; Interleukin-11; Neoplasms; Stem Cell Factor | 1999 |
6 trial(s) available for amifostine anhydrous and losartan potassium
| Article | Year |
|---|---|
Fractionated carboplatin radiosensitization: a phase I dose-escalation study.
Topics: Adult; Aged; Amifostine; Antineoplastic Agents; Carboplatin; Combined Modality Therapy; Erythropoietin; Female; Granulocyte Colony-Stimulating Factor; Humans; Lung Neoplasms; Male; Middle Aged; Pelvic Neoplasms; Radiation-Protective Agents; Radiation-Sensitizing Agents; Recombinant Proteins | 1998 |
Amifostine in the treatment of low-risk myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Amifostine; Blood Cell Count; Erythropoietin; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Pancytopenia; Pilot Projects; Radiation-Protective Agents; Receptors, Transferrin; Thrombopoietin | 2000 |
Preliminary results of amifostine administration in combination with recombinant human erythropoietin in patients with myelodysplastic syndromes.
Topics: Aged; Amifostine; Anemia, Refractory; Anemia, Refractory, with Excess of Blasts; Blood Transfusion; Bone Marrow Cells; Cytoprotection; Erythropoietin; Female; Humans; Male; Myelodysplastic Syndromes; Outpatients; Recombinant Proteins | 2001 |
Amifostine in combination with erythropoietin and G-CSF promotes multilineage hematopoiesis in patients with myelodysplastic syndrome.
Topics: Aged; Aged, 80 and over; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Cell Lineage; Erythropoietin; Granulocyte Colony-Stimulating Factor; Hematopoiesis; Humans; Middle Aged; Myelodysplastic Syndromes; Treatment Outcome | 2001 |
Moist skin care can diminish acute radiation-induced skin toxicity.
Topics: Amifostine; Azulenes; Clinical Trials as Topic; Data Interpretation, Statistical; Dose Fractionation, Radiation; Double-Blind Method; Erythropoietin; Female; Head and Neck Neoplasms; Hospitalization; Humans; Length of Stay; Lipids; Male; Multicenter Studies as Topic; Ointment Bases; Ointments; Particle Accelerators; Placebos; Radiation Injuries; Radiation-Protective Agents; Radiotherapy; Radiotherapy Dosage; Recombinant Proteins; Sesquiterpenes; Sesquiterpenes, Guaiane; Skin; Skin Care; Time Factors; Urea | 2003 |
Randomized phase 2 study of subcutaneous amifostine versus epoetin-alpha given 3 times weekly during concurrent chemotherapy and hyperfractionated radiotherapy for limited-disease small cell lung cancer.
Topics: Aged; Amifostine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Small Cell; Combined Modality Therapy; Dose Fractionation, Radiation; Drug Administration Schedule; Epoetin Alfa; Erythropoietin; Female; Humans; Injections, Subcutaneous; Lung Neoplasms; Male; Middle Aged; Radiation-Protective Agents; Recombinant Proteins; Survival Analysis | 2008 |
8 other study(ies) available for amifostine anhydrous and losartan potassium
| Article | Year |
|---|---|
Amifostine alone and in combination with erythropoietin for the treatment of favorable myelodysplastic syndrome.
Topics: Aged; Amifostine; Drug Therapy, Combination; Erythropoietin; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Recombinant Proteins | 2001 |
Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes.
Topics: Aged; Aged, 80 and over; Amifostine; Drug Evaluation; Drug Therapy, Combination; Erythropoietin; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Recombinant Proteins; Treatment Outcome | 2002 |
Amifostine plus erythropoietin in a patient with low-risk myelodysplastic syndrome.
Topics: Aged; Aged, 80 and over; Amifostine; Anemia; Anemia, Iron-Deficiency; Drug Therapy, Combination; Erythropoietin; Female; Humans; Myelodysplastic Syndromes; Radiation-Protective Agents; Treatment Outcome | 2003 |
Protection against cisplatin-induced nephrotoxicity by recombinant human erythropoietin.
Topics: Amifostine; Animals; Antineoplastic Agents; Blood Urea Nitrogen; Cisplatin; Creatinine; Erythropoietin; Female; Hematocrit; Hemoglobins; Kidney; Rats; Rats, Wistar; Recombinant Proteins | 2003 |
[Short-term curative effect of amifostine combined with rhEPO on aged patients wilh myelodysplastic syndrome].
Topics: Aged; Aged, 80 and over; Amifostine; Drug Therapy, Combination; Erythropoietin; Humans; Male; Myelodysplastic Syndromes; Recombinant Proteins; Time Factors; Treatment Outcome | 2005 |
Recombinant human erythropoietin in comparison to amifostine against cisplatin-induced peripheral sensorial neurotoxicity in rats.
Topics: Amifostine; Animals; Cisplatin; Erythropoietin; Evoked Potentials, Somatosensory; Female; Neurons, Afferent; Neurotoxins; Rats; Rats, Wistar; Recombinant Proteins | 2006 |
[Amifostine used in the treatment of patients with myelodysplastic syndrome].
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Drug Therapy, Combination; Erythropoietin; Female; Humans; Male; Middle Aged; Myelodysplastic Syndromes; Recombinant Proteins | 2007 |
[Short-term curative effect of amifostine combined with rhbeta-EPO on patients with pure erythroid aplasia].
Topics: Aged, 80 and over; Amifostine; Anemia, Aplastic; Drug Therapy, Combination; Erythropoietin; Humans; Male; Recombinant Proteins; Treatment Outcome | 2008 |